Treatment of SARS with human interferons - PubMed (original) (raw)

Treatment of SARS with human interferons

J Cinatl et al. Lancet. 2003.

Erratum in

Lancet. 2003 Aug 30;362(9385):748

Abstract

Effective antiviral agents are needed to treat severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infection. We assessed the antiviral potential of recombinant interferons against two clinical isolates of SARS-CoV--FFM-1, from Frankfurt patients, and Hong Kong--replicated in Vero and Caco2 cells. Interferon beta was five to ten times more effective in Caco2 cells. Interferon alpha effectively inhibited SARS-CoV replication, but with a selectivity index 50-90 times lower than that for interferon beta. Interferon gamma was slightly better than interferon alpha in Vero cell cultures, but was completely ineffective in Caco2 cell cultures. Interferon beta could be useful alone or in combination with other antiviral drugs for the treatment of SARS.

PubMed Disclaimer

Figures

Figure

Effect of interferon β on replication of SARS-CoV strain: FFM-1 in Vero cells 72 h after infection Virus detected in serum with peroxidase staining. *Values represent mean (SD) from three experiments, each done in triplicate.

Comment in

Treatment of SARS with human interferons.
Antonelli G, Scagnolari C, Vicenzi E, Clementi M. Antonelli G, et al. Lancet. 2003 Oct 4;362(9390):1158; author reply 1158-9. doi: 10.1016/S0140-6736(03)14482-0. Lancet. 2003. PMID: 14550714 Free PMC article. No abstract available.
Treatment of SARS with human interferons.
Moriguchi H, Sato C. Moriguchi H, et al. Lancet. 2003 Oct 4;362(9390):1159. doi: 10.1016/S0140-6736(03)14484-4. Lancet. 2003. PMID: 14550718 Free PMC article. No abstract available.

Cited by

Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial.
Alavi Darazam I, Shokouhi S, Pourhoseingholi MA, Naghibi Irvani SS, Mokhtari M, Shabani M, Amirdosara M, Torabinavid P, Golmohammadi M, Hashemi S, Azimi A, Jafarazadeh Maivan MH, Rezaei O, Zali A, Hajiesmaeili M, Shabanpour Dehbsneh H, Hoseyni Kusha A, Taleb Shoushtari M, Khalili N, Soleymaninia A, Gachkar L, Khoshkar A. Alavi Darazam I, et al. Sci Rep. 2021 Apr 13;11(1):8059. doi: 10.1038/s41598-021-86859-y. Sci Rep. 2021. PMID: 33850184 Free PMC article. Clinical Trial.
Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use.
Antonelli G, Scagnolari C, Moschella F, Proietti E. Antonelli G, et al. Cytokine Growth Factor Rev. 2015 Apr;26(2):121-31. doi: 10.1016/j.cytogfr.2014.12.006. Epub 2014 Dec 30. Cytokine Growth Factor Rev. 2015. PMID: 25578520 Free PMC article. Review.
Coronaviruses and their therapy.
Haagmans BL, Osterhaus AD. Haagmans BL, et al. Antiviral Res. 2006 Sep;71(2-3):397-403. doi: 10.1016/j.antiviral.2006.05.019. Epub 2006 Jun 19. Antiviral Res. 2006. PMID: 16837072 Free PMC article. Review.
Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models.
Paragas J, Blatt LM, Hartmann C, Huggins JW, Endy TP. Paragas J, et al. Antiviral Res. 2005 Jun;66(2-3):99-102. doi: 10.1016/j.antiviral.2005.01.002. Epub 2005 Feb 15. Antiviral Res. 2005. PMID: 15911026 Free PMC article.
Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform.
Bojkova D, Reus P, Panosch L, Bechtel M, Rothenburger T, Kandler JD, Pfeiffer A, Wagner JUG, Shumliakivska M, Dimmeler S, Olmer R, Martin U, Vondran FWR, Toptan T, Rothweiler F, Zehner R, Rabenau HF, Osman KL, Pullan ST, Carroll MW, Stack R, Ciesek S, Wass MN, Michaelis M, Cinatl J Jr. Bojkova D, et al. iScience. 2023 Feb 17;26(2):105944. doi: 10.1016/j.isci.2023.105944. Epub 2023 Jan 7. iScience. 2023. PMID: 36644320 Free PMC article.

References

1. Drosten C, Gunther S, Preiser W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–1976. - PubMed
1. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361:2045–2046. - PMC - PubMed
1. Garcia S, Crance JM, Billecocq A. Quantitative real-time PCR detection of Rift Valley fever virus and its application to evaluation of antiviral compounds. J Clin Microbiol. 2001;39:4456–4461. - PMC - PubMed
1. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA. 1998;95:15623–15628. - PMC - PubMed
1. Pitkaranta A, Nokso-Koivisto J, Jantti V, Takala A, Kilpi T, Hovi T. Lowered yields of virus-induced interferon production in leukocyte cultures and risk of recurrent respiratory infections in children. J Clin Virol. 1999;14:199–205. - PMC - PubMed

Treatment of SARS with human interferons - PubMed (original) (raw)